Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Qiuyang Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3986-2911; OpenAlex author ID A5103275050. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 8

  1. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  2. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer. Co-author DOI 10.1002/mc.23627↗
  3. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Co-author DOI 10.1016/j.biopha.2019.109521↗
  4. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway. First author DOI 10.1002/mc.23011↗
  5. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Co-author DOI 10.1111/cpr.12428↗
  6. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1186/s12876-018-0891-y↗
  7. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. Co-author DOI 10.1186/s13046-018-0807-2↗
  8. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Co-author DOI 10.3892/or.2017.6036↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 5 shared papers, 2018–2025 · strength 0.56
  2. Yue Fu · 5 shared papers, 2017–2023 · strength 0.54
  3. Shangnan Dai · 3 shared papers, 2020–2025 · strength 0.49
  4. Junli Wu · 4 shared papers, 2017–2025 · strength 0.46
  5. Jishu Wei · 4 shared papers, 2017–2025 · strength 0.45
  6. Xinchun Liu · 4 shared papers, 2017–2023 · strength 0.42
  7. Yunpeng Peng · 3 shared papers, 2018–2025 · strength 0.39
  8. Kuirong Jiang · 3 shared papers, 2017–2025 · strength 0.36
  9. Lingdi Yin · 2 shared papers, 2018–2025 · strength 0.29
  10. Min Tu · 2 shared papers, 2018–2025 · strength 0.29
  11. Yi Miao · 2 shared papers, 2017–2023 · strength 0.24
  12. Peng Wang · 2 shared papers, 2017–2023 · strength 0.24
  13. Zipeng Lu · 1 shared paper, 2025 · strength 0.21
  14. Guangfu Wang · 1 shared paper, 2025 · strength 0.21
  15. Xiaole Zhu · 2 shared papers, 2018–2020 · strength 0.18
  16. Wentao Gao · 2 shared papers, 2017–2018 · strength 0.15
  17. Liming Tang · 1 shared paper, 2019 · strength 0.12
  18. Na Yao · 1 shared paper, 2019 · strength 0.12
  19. Dalai Xu · 1 shared paper, 2020 · strength 0.10
  20. Feng Zhu · 1 shared paper, 2020 · strength 0.10
  21. Yi Zhu · 1 shared paper, 2020 · strength 0.10
  22. Jun Yu · 1 shared paper, 2018 · strength 0.09
  23. Qiang Li · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.